Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46–61%) and 73% (67–80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33–55%] vs 63% [54–73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1.
Teclistamab是一种靶向BCMAxCD3的双特异性抗体，在三重暴露的复发/难治性多发性骨髓瘤患者中显示出较高的缓解率和持久的缓解。我们进行了一项回顾性研究，评估了IMWG免疫治疗工作组委员会内五个国家、9个学术中心治疗的210例患者中Teclistamab的疗效和安全性。这些患者均经过大量预处理，其中83%为三重难治性疾病，44%曾接受过BCMA靶向治疗。中位随访5.3个月后，在188例可评估疗效的患者中，总缓解率（ORR）为67%，其中55%达到非常好的部分缓解或更好。6个月无进展生存期（PFS）和总生存率分别为53%（95% CI，46–61%）和73%（67–80%）。与未接受过BCMA靶向治疗的患者相比，曾接受BCMA靶向治疗的患者ORR更低（58.3%对比74.0%；P=0.03），PFS也更短（6个月PFS：43%[95% CI, 33–55%]对比63%[54–73%]；对数秩P=0.004）。23%的患者在门诊接受了阶梯式剂量递增治疗。细胞因子释放综合征发生率为54%，感染发生率为56.2%，其中≥3级感染占22%。在这项多中心真实世界研究中，我们发现Teclistamab在大量预处理的多发性骨髓瘤患者中可引发快速缓解，其疗效和安全性特征与MajesTEC-1研究结果相当。
肿瘤(癌症)患者之家